FR2757169B1 - Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin - Google Patents

Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin

Info

Publication number
FR2757169B1
FR2757169B1 FR9615344A FR9615344A FR2757169B1 FR 2757169 B1 FR2757169 B1 FR 2757169B1 FR 9615344 A FR9615344 A FR 9615344A FR 9615344 A FR9615344 A FR 9615344A FR 2757169 B1 FR2757169 B1 FR 2757169B1
Authority
FR
France
Prior art keywords
protein
vaccine
preparation
especially useful
human cmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9615344A
Other languages
English (en)
Other versions
FR2757169A1 (fr
Inventor
Eric Prieur
Jacqueline Lule
Jean Luc Davignon
Christian Davrinche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9615344A priority Critical patent/FR2757169B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to AU54892/98A priority patent/AU5489298A/en
Priority to US09/319,264 priority patent/US6605467B2/en
Priority to JP52631998A priority patent/JP2001506494A/ja
Priority to CA002275340A priority patent/CA2275340A1/fr
Priority to PCT/FR1997/002285 priority patent/WO1998026074A1/fr
Priority to EP97951322A priority patent/EP0951554A1/fr
Publication of FR2757169A1 publication Critical patent/FR2757169A1/fr
Application granted granted Critical
Publication of FR2757169B1 publication Critical patent/FR2757169B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
FR9615344A 1996-12-13 1996-12-13 Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin Expired - Fee Related FR2757169B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR9615344A FR2757169B1 (fr) 1996-12-13 1996-12-13 Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
US09/319,264 US6605467B2 (en) 1996-12-13 1997-12-12 Fusion protein comprising the whole or part of the PP65 protein of human CMV, useable in particular for preparing a vaccine
JP52631998A JP2001506494A (ja) 1996-12-13 1997-12-12 特にワクチンの製造に用いることができるヒトｃｍｖのタンパク質ｐｐ６５の総てまたは一部を含んでなる融合タンパク質
CA002275340A CA2275340A1 (fr) 1996-12-13 1997-12-12 Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
AU54892/98A AU5489298A (en) 1996-12-13 1997-12-12 Fusion protein comprising the whole or part of the pp65 protein of human CM V useable in particular for preparing vaccine
PCT/FR1997/002285 WO1998026074A1 (fr) 1996-12-13 1997-12-12 Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
EP97951322A EP0951554A1 (fr) 1996-12-13 1997-12-12 Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615344A FR2757169B1 (fr) 1996-12-13 1996-12-13 Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin

Publications (2)

Publication Number Publication Date
FR2757169A1 FR2757169A1 (fr) 1998-06-19
FR2757169B1 true FR2757169B1 (fr) 1999-03-05

Family

ID=9498647

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9615344A Expired - Fee Related FR2757169B1 (fr) 1996-12-13 1996-12-13 Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin

Country Status (7)

Country Link
US (1) US6605467B2 (fr)
EP (1) EP0951554A1 (fr)
JP (1) JP2001506494A (fr)
AU (1) AU5489298A (fr)
CA (1) CA2275340A1 (fr)
FR (1) FR2757169B1 (fr)
WO (1) WO1998026074A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562345B1 (en) 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
FR2757169B1 (fr) * 1996-12-13 1999-03-05 Inst Nat Sante Rech Med Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
DE19910044A1 (de) * 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
AU5963500A (en) 1999-06-04 2000-12-28 Florian Kern Peptides for vaccinating against human cmv
US6579970B2 (en) 2000-03-21 2003-06-17 Genzyme Corporation Therapeutic anti-cytomegalovirus compounds
EP1612217A3 (fr) * 2000-03-27 2006-01-18 City of Hope Epitopes ctl peptidiques immunoréactifs du cytomégalovirus
US6861408B2 (en) 2000-05-31 2005-03-01 Genzyme Corporation Therapeutic anti-melanoma compounds
JP4099058B2 (ja) 2000-10-20 2008-06-11 シティ・オブ・ホープ ヒトサイトメガロウィルスｐｐ１５０の免疫反応性ペプチドｃｔｌエピトープ
ATE432285T1 (de) * 2003-07-11 2009-06-15 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
WO2006004661A1 (fr) * 2004-06-25 2006-01-12 Medimmune Vaccines, Inc. Cytomegalovirus humain de recombinaison et vaccins contenant des antigenes heterologues
WO2006110728A2 (fr) * 2005-04-12 2006-10-19 The Uab Research Foundation Agregats de tegument immunogenes
US8460913B2 (en) * 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997878A (en) * 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
DE69232265T2 (de) * 1992-06-25 2002-08-08 City Of Hope Duarte Induktion von cytolytischen t-lymphocyten mit polypeptiden des cytomegalievirus
IT1266740B1 (it) * 1994-07-01 1997-01-14 Maria Paola Landini Materiale proteico ricombinante legante anticorpi contro il citomegalovirus umano, reagenti diagnostici derivati da tale
EP0702083A3 (fr) * 1994-07-26 1997-01-15 Biotest Ag Polypeptides et protéines fusionnées contenant la structure à lecture ouverte UL57 ou la séquence C-terminal de la protéine pp150 de tégument de HCMV, oligonucléotides et trousses diagnostiques correspondantes
DE4426453C1 (de) * 1994-07-26 1995-11-02 Biotest Ag Rekombinant hergestellte Fusionsproteine des Cytomegalievirus und diese enthaltende diagnostische Testkits
FR2723849B1 (fr) * 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5800981A (en) * 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
FR2757169B1 (fr) * 1996-12-13 1999-03-05 Inst Nat Sante Rech Med Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin

Also Published As

Publication number Publication date
AU5489298A (en) 1998-07-03
WO1998026074A1 (fr) 1998-06-18
FR2757169A1 (fr) 1998-06-19
EP0951554A1 (fr) 1999-10-27
JP2001506494A (ja) 2001-05-22
US6605467B2 (en) 2003-08-12
CA2275340A1 (fr) 1998-06-18
US20020156251A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
FR2757169B1 (fr) Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
FR2750865B1 (fr) Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
DE69622735T2 (de) Lyophilisierte stabile pharmazeutische formulierung
NO996133D0 (no) Olje-i-vann-vaksinesammensetninger
ATE276762T1 (de) Stabile lyophilisierte pharmazeutische zubereitungen von mono- oder polykonalen antikörpern
DE69733994D1 (de) Sauger zur medikamentenverabreichung
FI973278A0 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
ATE279193T1 (de) Pharmazeutische zubereitung von moxifloxacin
EE05000B1 (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
BR9707418A (pt) Preparação medicinal e um método de ação medicinal sobre o organismo humano
AU4784693A (en) Blockade of protein c activation reduces microvascular surgical blood loss
DE69532106D1 (de) Maltose Phospharylase, Trehalose Phophorylase, Plesiomonasstamm, und Herstellung von Trehalose
EE9900034A (et) Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine
DK0925273T3 (da) Farmaceutiske præparater indeholdende 4-oxo-butansyrer
EE03511B1 (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
DE69513618D1 (de) Blutverträgliche, scherempfindliche Formulierungen
AU3552797A (en) Vaccine preparations
HU9601608D0 (en) Marek`s disease vaccine
FI953257A0 (fi) Rekombinanttinen ihmisen prostaspesifinen antigeenRekombinanttinen ihmisen prostaspesifinen antigeeni ja sen käytöt i ja sen käytöt
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine
FR2692898B1 (fr) Procédé d'obtention de protéines membranaires, et utilisation de ces protéines dans un but de diagnostic ou de vaccination.
EE9900092A (et) PTX-tundlikud G-valgud, nende valmistamine ja kasutamine
AU5520796A (en) Peptide-based vaccine against papillomavirus infection
ATA77096A (de) Pharmazeutische präparation
FR2755861B1 (fr) Potence medicale individuelle portee

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20060831